GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » 3-Year ROIIC %

Apollon Formularies (AQSE:APOL) 3-Year ROIIC % : -86.71% (As of Dec. 2021)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Apollon Formularies's 3-Year ROIIC % for the quarter that ended in Dec. 2021 was -86.71%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Apollon Formularies's 3-Year ROIIC % or its related term are showing as below:

AQSE:APOL's 3-Year ROIIC % is ranked worse than
87.68% of 1031 companies
in the Drug Manufacturers industry
Industry Median: 0.36 vs AQSE:APOL: -86.71

Apollon Formularies 3-Year ROIIC % Historical Data

The historical data trend for Apollon Formularies's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies 3-Year ROIIC % Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -592.45 - - 5.84 -86.71

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.84 - -86.71 - -

Competitive Comparison of Apollon Formularies's 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's 3-Year ROIIC % falls into.



Apollon Formularies 3-Year ROIIC % Calculation

Apollon Formularies's 3-Year ROIIC % for the quarter that ended in Dec. 2021 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -0.762 (Dec. 2021) - -0.364 (Dec. 2018) )/( 2.709 (Dec. 2021) - 2.25 (Dec. 2018) )
=-0.398/0.459
=-86.71%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Apollon Formularies  (AQSE:APOL) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Apollon Formularies 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 05-22-2015

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

Richard Pzena Reduces APOL as Phoenix Rises for Others

By Sally Jones Sally Jones 03-11-2013

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015